# A Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults

> **NCT02837692** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 140 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JNJ-42847922 10 milligram (mg)
- **DRUG:** JNJ-42847922 20 mg
- **DRUG:** JNJ-42847922 40 mg
- **DRUG:** JNJ-42847922 60 or 80 mg

## Key facts

- **NCT ID:** NCT02837692
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-08
- **Primary completion:** 2017-09-07
- **Final completion:** 2017-09-11
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2017-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02837692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02837692, "A Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02837692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*